GABRIELA Jaramillo-Koupermann

Dr. GABRIELA Jaramillo-Koupermann

Hospital de Especialidades Eugenio Espejo, Quito, Pichincha, Ecuador
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2013 in The American Journal of the Medical Sciences
Verified
Journal Article
Closed access
PDF file
Andrés López-CortésAndrés López-Cortés
Andrés López-Cortés
GJGABRIELA Jaramillo-Koupermann
GABRIELA Jaramillo-Koupermann
MMMaría J. Muñoz
María J. Muñoz
Alejandro Cabrera-AndradeAlejandro Cabrera-Andrade
Alejandro Cabrera-Andrade
CECarolina Echeverría
Carolina Echeverría
NVNicolás Vivar
Nicolás Vivar

15 October 2019 in The Pharmacogenomics Journal
Verified
Journal Article
Closed access
PDF file
Andrés López-CortésAndrés López-Cortés
Andrés López-Cortés
CPCesar Paz-y-Mino
Cesar Paz-y-Mino
SGSantiago Guerrero
Santiago Guerrero
GJGABRIELA Jaramillo-Koupermann
GABRIELA Jaramillo-Koupermann
ÁCÁngela León Cáceres
Ángela León Cáceres
NSNéstor W. Soria
Néstor W. Soria

1 September 2019 in European Journal of Cancer
Verified
Journal Article
Closed access
AVAdriana Della Valle
Adriana Della Valle
BRBenedito Mauro Rossi
Benedito Mauro Rossi
EPEdenir Palmero
Edenir Palmero
MAMarina Antelo
Marina Antelo
CVCarlos Alberto Vaccaro
Carlos Alberto Vaccaro
MDMev Dominguez-Valentin
Mev Dominguez-Valentin

8 January 2021 in BMC Cancer
Verified
Journal Article
Open access
PDF file
APANDREA PAOLA SOLIS PAZMINO
ANDREA PAOLA SOLIS PAZMINO
JSJorge Salazar-Vega
Jorge Salazar-Vega
ELEddy Lincango-Naranjo
Eddy Lincango-Naranjo
CGCristhian Garcia
Cristhian Garcia
GJGABRIELA Jaramillo-Koupermann
GABRIELA Jaramillo-Koupermann
JBJuan P. Brito
Juan P. Brito
Background: In contrast to the rapid increase in thyroid cancer incidence, the mortality has remained low and stable over the last decades. In Ecuador, however, thyroid cancer mortality has increased. The objective of this study is to determine possible drivers of high rates of thyroid cancer mortality, through a cross-sectional analysis of all patients attending a thyroid cancer referral center in Ecuador.Methods: From June 2014 to December 2017, a cross-sectional study was conducted at the Hospital de Especialidades Eugenio Espejo, a regional reference public hospital for endocrine neoplasia in adults in Quito, Ecuador. We identified the mechanism of detection, histopathology and treatment modalities from a patient interview and review of clinical records.Results: Among 452 patients, 74.8% were young adults and 94.2% (426) were female. 13.7% had a family history of thyroid cancer, and patients’ median tumor size was 2 cm. The incidental finding was 54.2% whereas 45.8% was non-incidental. Thyroid cancer histology reported that 93.3% had papillary thyroid cancer (PTC), 2.7% follicular, 1.5% Hurtle cells, 1.6% medullary, 0.7% poor differentiated, and 0.2% anaplastic carcinoma. The mean MACIS (metastasis, age, completeness, invasion, and size) score was 4.95 (CI 4.15–5.95) with 76.2% of the thyroid cancer patients having MACIS score less than or equal to 6. The very low and low risk of recurrence was 18.1% (79) and 62% (271) respectively. An analysis of 319 patients with non-metastatic thyroid cancer showed that 10.7% (34) of patients had surgical complications. Moreover, around 62.5% (80 from 128 patients with thyroglobulin laboratory results) of TC patients had a stimulated-thyroglobulin value equal or higher than 2 ng/ml. Overall, a poor surgical outcome was present in 35.1% (112) patients. Out of 436 patients with differentiated thyroid carcinoma, 86% (375) received radioactive iodine.Conclusion: Thyroid cancer histological characteristics and method of diagnosis are like those described in other reports without any evidence of the high frequency of aggressive thyroid cancer histology. However, we observed evidence of overtreatment and poor surgical outcomes that demand additional studies to understand their association with thyroid cancer mortality in Ecuador.

Verified
Journal Article
Open access
PDF file
Alejandro Cabrera-AndradeAlejandro Cabrera-Andrade
Alejandro Cabrera-Andrade
Andrés López-CortésAndrés López-Cortés
Andrés López-Cortés
GJGABRIELA Jaramillo-Koupermann
GABRIELA Jaramillo-Koupermann
CPCesar Paz-y-Mino
Cesar Paz-y-Mino
YPYunierkis Pérez-Castillo
Yunierkis Pérez-Castillo
ETEduardo Tejera
Eduardo Tejera
Osteosarcoma is the most common subtype of primary bone cancer, affecting mostly adolescents. In recent years, several studies have focused on elucidating the molecular mechanisms of this sarcoma; however, its molecular etiology has still not been determined with precision. Therefore, we applied a consensus strategy with the use of several bioinformatics tools to prioritize genes involved in its pathogenesis. Subsequently, we assessed the physical interactions of the previously selected genes and applied a communality analysis to this protein–protein interaction network. The consensus strategy prioritized a total list of 553 genes. Our enrichment analysis validates several studies that describe the signaling pathways PI3K/AKT and MAPK/ERK as pathogenic. The gene ontology described TP53 as a principal signal transducer that chiefly mediates processes associated with cell cycle and DNA damage response It is interesting to note that the communality analysis clusters several members involved in metastasis events, such as MMP2 and MMP9, and genes associated with DNA repair complexes, like ATM, ATR, CHEK1, and RAD51. In this study, we have identified well-known pathogenic genes for osteosarcoma and prioritized genes that need to be further explored.

22 November 2020 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
Alejandro Cabrera-AndradeAlejandro Cabrera-Andrade
Alejandro Cabrera-Andrade
Andrés López-CortésAndrés López-Cortés
Andrés López-Cortés
GJGABRIELA Jaramillo-Koupermann
GABRIELA Jaramillo-Koupermann
Humbert G. DíazHumbert G. Díaz
Humbert G. Díaz
ASAlejandro Pazos Sierra
Alejandro Pazos Sierra
ETEduardo Tejera
Eduardo Tejera
Osteosarcoma is the most common type of primary malignant bone tumor. Although nowadays 5-year survival rates can reach up to 60–70%, acute complications and late effects of osteosarcoma therapy are two of the limiting factors in treatments. We developed a multi-objective algorithm for the repurposing of new anti-osteosarcoma drugs, based on the modeling of molecules with described activity for HOS, MG63, SAOS2, and U2OS cell lines in the ChEMBL database. Several predictive models were obtained for each cell line and those with accuracy greater than 0.8 were integrated into a desirability function for the final multi-objective model. An exhaustive exploration of model combinations was carried out to obtain the best multi-objective model in virtual screening. For the top 1% of the screened list, the final model showed a BEDROC = 0.562, EF = 27.6, and AUC = 0.653. The repositioning was performed on 2218 molecules described in DrugBank. Within the top-ranked drugs, we found: temsirolimus, paclitaxel, sirolimus, everolimus, and cabazitaxel, which are antineoplastic drugs described in clinical trials for cancer in general. Interestingly, we found several broad-spectrum antibiotics and antiretroviral agents. This powerful model predicts several drugs that should be studied in depth to find new chemotherapy regimens and to propose new strategies for osteosarcoma treatment.